Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells

Respiratory Research

Yoon Soo Chang²  Chul Min Ahn²  Joon Chang²  Hyung Jung Kim²  Se Kyu Kim²  Arum Kim¹  Eun Young Kim² 

[1] Biomedical Research Center, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul 135-720, Republic of Korea;Department of Internal Medicine, Yonsei University College of Medicine, 50-1, Yonsei-ro, Seodaemun-gu, Seoul 120-752, Republic of Korea

关键词: EMT;    Rictor;    Raptor;    E-Cadherin repressor complexes;    mTORC2;    mTORC1;    mTOR;   

Others  :  790387
DOI  :  10.1186/1465-9921-15-26

 received in 2013-12-17, accepted in 2014-02-18,  发布年份 2014

【 摘 要 】

Background

mTOR, which can form mTOR Complex 1 (mTORC1) or mTOR Complex 2 (mTORC2) depending on its binding partners, is frequently deregulated in the pulmonary neoplastic conditions and interstitial lung diseases of the patients treated with rapalogs. In this study, we investigated the relationship between mTOR signaling and epithelial mesenchymal transition (EMT) by dissecting mTOR pathways.

Methods

Components of mTOR signaling pathway were silenced by shRNA in a panel of non-small cell lung cancer cell lines and protein expression of epithelial and mesenchymal markers were evaluated by immunoblotting and immunocytochemistry. mRNA level of the E-cadherin repressor complexes were evaluated by qRT-PCR.

Results

IGF-1 treatment decreased expression of the E-cadherin and rapamycin increased its expression, suggesting hyperactivation of mTOR signaling relates to the loss of E-cadherin. Genetic ablation of rapamycin-insensitive companion of mTOR (Rictor), a component of mTORC2, did not influence E-cadherin expression, whereas genetic ablation of regulatory-associated protein of mTOR (Raptor), a component of mTORC1, led to a decrease in E-cadherin expression at the mRNA level. Increased phosphorylation of AKT at Ser473 and GSK-3β at Ser9 were observed in the Raptor-silenced NSCLC cells. Of the E-cadherin repressor complexes tested, Snail, Zeb2, and Twist1 mRNAs were elevated in raptor-silenced A549 cells, and Zeb2 and Twist1 mRNAs were elevated in Raptor-silenced H2009 cells. These findings were recapitulated by treatment with the GSK-3β inhibitor, LiCl. Raptor knockdown A549 cells showed increased expression of N-cadherin and vimentin with mesenchymal phenotypic changes.

Conclusions

In conclusion, selective inhibition of mTORC1 leads to hyperactivation of the AKT/GSK-3β pathway, inducing E-cadherin repressor complexes and EMT. These findings imply the existence of a feedback inhibition loop of mTORC1 onto mTORC2 that plays a role in the homeostasis of E-cadherin expression and EMT, requiring caution in the clinical use of rapalog and selective mTORC1 inhibitors.

【 授权许可】

   
2014 Kim et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 7.

Figure 5.

【 参考文献 】

• [1]Hay N, Sonenberg N: Upstream and downstream of mTOR. Genes Dev 1926–1945, 2004:18.
• [2]Peterson TR, Laplante M, Thoreen C, Sancak Y, Kang SA, Kuehl WM, Gray NS, Sabatini DM: DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009, 137:873-886.
• [3]Guertin DA, Sabatini DM: Defining the role of mTOR in cancer. Cancer cell 2007, 12:9-22.
• [4]Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
• [5]Henske EP, McCormack FX: Lymphangioleiomyomatosis — a wolf in sheep’s clothing. J Clin Invest 2012, 122:3807-3816.
• [6]Morelon E, Stern M, Israël Biet D, Correas JM, Danel C, Mamzer Bruneel MF, Peraldi MN , Kreis H: Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001, 72:787-790.
• [7]Gartrell B, Ying J, Sivendran S, Boucher K, Choueiri T, Sonpavde G, Oh W, Agarwal N, Galsky M: Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Target Oncol 2013, 1-10.
• [8]Lau M, Leung PC: The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells. Cancer Lett 2012, 326:191-198.
• [9]Huber A, Bodenmiller B, Uotila A, Stahl M, Wanka S, Gerrits B, Aebersold R, Loewith R: Characterization of the rapamycin-sensitive phosphoproteome reveals that Sch9 is a central coordinator of protein synthesis. Genes Dev 1929–1943, 2009:23.
• [10]Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RF: The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004, 166:213-223.
• [11]Hsu P, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, Peterson TR, Choi Y, Gray NS, Yaffe MB, Marto JA, Sabatini DM: The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011, 332:1317-1322.
• [12]Dowling RJO, Topisirovic I, Fonseca BD, Sonenberg N: Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta 1804, 2010:433-439.
• [13]McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP III, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee H, Krischer JP, Trapnell BC, for the National Institutes of Health Rare Lung Diseases Consortium and the MILES Trial Group: Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011, 364:1595-1606.
• [14]O’Reilly KE, Rojo F, She Q, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
• [15]Endo M, Johkoh T, Kimura K, Yamamoto N: Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer 2006, 52:135-140.
• [16]Kim A, Kim EY, Cho EN, Kim HJ, Kim SK, Chang J, Ahn CM, Chang YS: Notch1 destabilizes the adherens junction complex through upregulation of the Snail family of E-cadherin repressors in non-small cell lung cancer. Oncol Rep 2013, 30:1423-1429.
• [17]Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung M: Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004, 6:931-940.
• [18]Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, Watson PC, Howe CJ, Doyle T, Pointon K, Cross JJ, Tattersfield AE, Kingswood JC, Sampson JR: Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res 2011, 17:4071-4081.
• [19]Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G: Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 2005, 352:1317-1323.
• [20]Rizell M, Andersson M, Cahlin C, Hafström L, Olausson M, Lindnér P: Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol 2008, 13:66-70.
• [21]Bjedov I, Toivonen JM, Kerr F, Slack C, Jacobson J, Foley A, Partridge L: Mechanisms of life span extension by rapamycin in the fruit Fly drosophila melanogaster. Cell Metab 2010, 11:35-46.
• [22]Howard L, Gopalan D, Griffiths M, Mahadeva R: Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate. Chest 2006, 129:1718-1721.
• [23]Garrean S, Massad MG, Tshibaka M, Hanhan Z, Caines AE, Benedetti E: Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients. Clin Transplant 2005, 19:698-703.
• [24]Augustine J, Bodziak KA, Hricik DE: Use of sirolimus in solid organ transplantation. Drugs 2007, 67:369-391.
• [25]Depuydt P, Nollet J, Benoit D, Praet M, Caes F: Fatal acute pulmonary injury associated with everolimus. Ann Pharmacother 2012, 46:e7-e7.
• [26]Delgado JF, Torres J, José Ruiz-Cano M, Sánchez V, Escribano P, Borruel S, MarÃa Cortina J, de la Calzada CS: Sirolimus-associated interstitial pneumonitis in 3 heart transplant recipients. J Heart Lung Transplant 2006, 25:1171-1174.
• [27]Aparicio G, Calvo MB, Medina V, Fernández O, Jiménez P, Lema M, Figueroa A, Antón Aparicio LM: Comprehensive lung injury pathology induced by mTOR inhibitors. Clin Transl Oncol 2009, 11:499-510.
• [28]Wu Z-Q, Li X-Y, Hu CY, Ford M, Kleer CG, Weiss SJ: Canonical Wnt signaling regulates Slug activity and links epithelial–mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression. Proc Natl Acad Sci USA 2012, 109:16654-16659.
• [29]Montero JC, Chen X, OcaÃa A, Pandiella A: Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications. Mol Cancer Ther 2012, 11:1342-1352.
• [30]Ferron GM, Jusko WJ: Species differences in sirolimus stability in humans, rabbits, and rats. Drug Metab Dispos 1998, 26:83-84.